Patents Assigned to TheraMAB LLC
  • Use of an active substance binding to CD28 for producing a pharmaceutical composition for activating and expanding T cells
    Patent number: 9119840
    Abstract: The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the B-CLL.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: September 1, 2015
    Assignee: THERAMAB LLC
    Inventor: Thomas Hanke
  • Use of a CD28 binding substance for making a pharmaceutical composition
    Patent number: 8389016
    Abstract: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: March 5, 2013
    Assignee: Theramab LLC
    Inventor: Thomas Hunig
  • Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes
    Patent number: 8334102
    Abstract: The invention teaches human-compatible monoclonal antibodies which are specific against human CD28 and human T-lymphocytes of several to all subgroups to activate without occupancy of an antigen receptor of the human T-lymphocytes and thus antigen-non-specifically.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: December 18, 2012
    Assignee: Theramab LLC
    Inventor: Thomas Hunig
  • USE OF A CD258 BINDING PHARMACEUTICAL SUBSTRANCE FOR MAKING A PHARMACEUTICAL COMPOSITION WITH DOSE-DEPENDENT EFFECT
    Publication number: 20120219553
    Abstract: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit.
    Type: Application
    Filed: September 1, 2011
    Publication date: August 30, 2012
    Applicant: TheraMAB LLC
    Inventors: Thomas Hanke, Chia-Huey Lin
  • Microparticle with cd28-specific monoclonal antibodies
    Patent number: 7868143
    Abstract: The invention relates to microparticles with a support structure and CD28-specific superagonistic monoclonal antibodies (mAbs) bonded to the support structure or a compound mimicking the above.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: January 11, 2011
    Assignee: TheraMAB LLC
    Inventor: Thomas Hünig